Lead Product(s): Remestemcel-L
Therapeutic Area: Gastroenterology Product Name: Ryoncil
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Cleveland Clinic
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2020
Mesoblast intends to confirm the potential for remestemcel-L to induce luminal healing and early remission in a wider spectrum of diseases with severe inflammation of the gut, in addition to steroid-refractory aGVHD. The trial has been commenced at the Cleveland Clinic.